HOUSTON, Texas, April 2, 2024 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced today that former Deputy General Counsel of the U.S. Department of Federal Affairs announced the appointment of William (“Bill”) A. Hudson, Jr., Veterans Affairs, has been appointed to the Company's Military and Governmental Advisory Committee (the “Advisory Committee”). Nexalin's advisory board provides strategic advice and counsel to support the advancement of the company's non-invasive, frequency-based deep brain stimulators in the U.S. military and government agencies.
Mr. Hudson is a partner in the Washington, DC office of Tully Rinkey PLLC, where his practice focuses on military, security clearance, and federal employment law. Prior to joining the company, Mr. Hudson served as President and CEO of Hudson Consulting. Hudson Consulting is committed to advising private industry in forming effective partnerships with government agencies, non-government organizations, and businesses to develop innovative support strategies for successful societal development. is focused on. Law and policy initiatives.
Mr. Hudson served as Acting General Counsel for the Department of Veterans Affairs (VA) from November 10, 2019 to January 20, 2021. Serves as legal advisor to the Department's Chief Legal Officer and Secretary of Veterans Affairs, and coordinates the work of the Office of General Counsel (OGC) Central Office Legal Group, OGC District Chief Counsel Office, and OGC National Practice Group. , provides legal services in areas including all of VA's Veterans Programs, Personnel, Torts, and Legal Affairs. General Law Subjects. Prior to joining VA, Mr. Hudson served as Senior Counsel and Director of Congressional Research in the Office of the General Counsel at the Department of Defense (DoD). He previously served twice as Deputy General Counsel (Legal Affairs) in the Department of Defense's Office of General Counsel. Mr. Hudson is a recipient of the Department of Veterans Affairs' Distinguished Service Award, and he is a five-time recipient of the Secretary of Defense's Award for Outstanding Civilian Achievement.
Mr. Hudson retired from the U.S. Army as a colonel in 2010 after more than 27 years of active duty. He holds a Master of Science degree in National Security Strategy from the National Military University. He received his Master of Laws degree from the Judge Advocate General's Law Center and School. He holds a J.D. from the University of South Carolina School of Law. He holds a Bachelor of Arts degree from The Citadel Military College in South Carolina. He is also a graduate of the U.S. Army Command and General Staff College.
Mark White, CEO of Nexalin Technology, said: “I am honored to welcome Col. Bill Hudson to the Military and Governmental Advisory Council. Bill has held senior positions in the Department of Veterans Affairs and the Department of Defense, making him uniquely qualified to lead these complex agencies. He also has extensive experience in forming public-private partnerships and has deep relationships at all levels of government, which will be invaluable in pursuing collaboration with various government agencies. We leverage his unique skillset to address the devastating effects of PTSD, TBI, anxiety, depression, insomnia, and other targeted We look forward to bringing new drug-free treatments to active duty military, veterans, and others suffering from symptoms.”
Mr Hudson said: “I am honored to support Nexalin’s mission to provide effective, drug-free treatment alternatives to patients with a variety of often debilitating mental health conditions. We look forward to making our contribution and helping advance the commercialization of this technology to improve health care outcomes for America's veterans who deserve the best possible care. Nexalin's new advanced 15 mA Given the growing body of clinical evidence supporting the efficacy and potential of waveforms, we truly believe that this technology has great potential and are leveraging our expertise and network to provide new treatments for these patients. I look forward to bringing you hope.”
About Nexalin Technology, Inc.
Nexalin designs and develops innovative and unique neurostimulation products to combat the ongoing global mental health epidemic. Nexilin's non-invasive products are undetectable to the human body and were developed to provide relief to people suffering from mental health issues. Nexalin uses bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical device can penetrate deep midbrain structures associated with mental health disorders. Nexalin believes the deeper penetrating waveforms of its next-generation devices will enhance patient responses without side effects. Nexalin Gen-2 15 milliampere (mA) neurostimulator was recently approved by the National Pharmaceutical Administration (NMPA) as a treatment for insomnia and depression in China. Additional information about our company can be found below. https://nexalin.com/.
Forward-looking statements
This press release contains statements that constitute “forward-looking statements.” These statements relate to future events or Nexalin's future financial performance. Statements that refer to expectations, projections or other characterizations of future events or conditions, or that are not statements of historical fact (such as statements that Nexalin or its management “believes”, “anticipates”, “expects”, (“anticipates,” “plans,” “intends” and similar expressions) do not express the possibility that actual events or actual results of Nexalin will differ materially from those expressed in the forward-looking statements. These statements should be considered forward-looking statements that involve certain risks and uncertainties. Forward-looking statements are subject to a number of conditions, many of which are described in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2023. Including, are beyond our control. Filings filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC's website. www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. Such forward-looking statements are made as of the date hereof and may become outdated over time. We undertake no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
contact:
Crescendo Communications, LLC
Phone number: (212) 671-1020
Email: NXL@crescendo-ir.com
Dave Gentry, CEO
Red Chip Companies Co., Ltd.
407-491-4498
NXL@redchip.com
